Recursion Pharmaceuticals, Inc.RXRXNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank91
3Y CAGR+50.1%
5Y CAGR-15.9%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
+50.1%/yr
Quarterly compound
5Y CAGR
-15.9%/yr
Recent acceleration
Percentile
P91
Near historical high
vs 5Y Ago
0.4x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 60.74% |
| Q3 2025 | -53.58% |
| Q2 2025 | 42.09% |
| Q1 2025 | -14.32% |
| Q4 2024 | -94.90% |
| Q3 2024 | 27.97% |
| Q2 2024 | 19.63% |
| Q1 2024 | -38.10% |
| Q4 2023 | -1.59% |
| Q3 2023 | -8.08% |
| Q2 2023 | 7.98% |
| Q1 2023 | -63.84% |
| Q4 2022 | 17.96% |
| Q3 2022 | 11.49% |
| Q2 2022 | -179.63% |
| Q1 2022 | 226.54% |
| Q4 2021 | -85.06% |
| Q3 2021 | 1.80% |
| Q2 2021 | -9.42% |
| Q1 2021 | -458.74% |
| Q4 2020 | 144.06% |
| Q3 2020 | -16.51% |
| Q2 2020 | 6.27% |
| Q1 2020 | 0.00% |